Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
$51.5
-0.75 (-1.4%)· Live
| Market cap | 3B | |
|---|---|---|
| Revenue (ttm) | 776.8M | |
| Net income (ttm) | -29M | |
| EPS (ttm) | $-0.51 | |
| Shares out | 58M | |
| P/E (forward) | 19.6x | |
| Volume | 854,620 | |
| Beta | 0.57 | |
| Price target | $61.6 | +19.5% |
Market data
Price
Recent price action with selectable time range.
Financial snapshot
- Revenue (ttm)
- 776.8M
- Net income (ttm)
- -29M
- EPS (ttm)
- $-0.51
- P/E (forward)
- 19.6x
- Market cap
- 3B
Fair-value bridge
- Current price
- $51.5
Analyst consensus
Recommendation
Strong Buy
Price target
$61.6
+19.5%
In the news
Latest news · SUPN
Recent company headlines from major financial publishers.
Valuation
- Market cap
- 3B
- P/E (forward)
- 19.6x
- P/S
- 3.8x
- P/B
- 2.8x
- PEG
- 0.71
- EV / EBITDA
- 21.6x
Profitability
- Gross margin
- 74.1%
- Operating margin
- 3.3%
- ROE
- -2.8%
- ROA
- 1.1%
- ROIC
- 3.3%
Balance sheet
- Debt / equity
- 0.04
- Current ratio
- 1.96
- Quick ratio
- 1.51
Trading
- Beta
- 0.57
- Volume
- 854,620
- Dividend yield
- 0.0%
Calendar
Next earnings
Upcoming earnings date and setup when available.
Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector percentile context
Refreshed 2026-05-10 22:07 UTC
Forward P/E19.6
P25 n/aP50 n/aP75 n/a
Trailing P/En/a
P25 n/aP50 n/aP75 n/a
ROE-2.8
P25 n/aP50 n/aP75 n/a
ROIC3.3
P25 n/aP50 n/aP75 n/a
Benchmarks · 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
All SUPN indicators
Market & fundamental data
Available fields
247
Groups with data
11
Currency
USD
Showing 247 of 247 available metrics for this ticker.
Deeper analysis on SUPN
14 sections in the full report · jump straight to what you need
Forecast
Bull, base, and bear cases with expected-return framing.
Valuation
Fair-value bridge, DCF, owner earnings, and peer multiples.
Sensitivity
Cost-of-equity and terminal-growth stress table.
Risks
Kill scenarios, soft-pass flags, and downside catalysts.
Earnings
Next earnings setup and beat / inline / miss thresholds.
Position sizing
Entry, exit, conviction, and quarterly monitoring rules.
Financials
Revenue, margins, cash flow, and balance-sheet context.
Peers
Relative valuation and profitability against the cohort.
Moat
Economic-profit evidence and competitive advantage risk.
Industry cycle
Sector phase, capital cycle, and secular tailwinds.
Scorecard
Six-factor overlay and 9-category weighted scorecard.
Recommendation
Final action, action steps, opportunity, and biggest risk.
Perspectives
Growth, value, and income investor reads.
Archive
Prior monthly reports and rating changes.
Frequently asked questions
About this SUPN report
What is the current SUPN stock rating?
Supernus Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.
Where can I read the full SUPN analysis?
The full report lives at /stocks/SUPN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.
What fair-value range is used for SUPN?
The latest report frames SUPN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.
How often is the SUPN page updated?
The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.